Cyclacel Pharmaceuticals, Inc. - Common Stock (CYCC)

The US market regular session of Tuesday is over, let's have a look at the top gainers and losers in the after hours session today.

Let's have a look at the stocks with an unusual volume in today's session.

Let's delve into the US markets on Tuesday and uncover the stocks that are experiencing notable gaps in today's session. Below, you'll find the gap up and gap down stocks.

The US market is yet to commence its session on Tuesday, but let's get a preview of the pre-market session and explore the top gainers and losers driving the early market movements.

The US market regular session of Monday is over, let's have a look at the top gainers and losers in the after hours session today.

After the conclusion of the US market's regular session on Wednesday, let's examine the after-hours session and unveil the notable performers among the top gainers and losers.

Cyclacel Pharmaceuticals shares are trading higher by 77% during Friday's session. The company announced a securities purchase agreement with investor David Lazar.

CYCC stock results show that Cyclacel Pharmaceuticals beat analyst estimates for earnings per share but missed on revenue for the second quarter of 2024.